// App-Quantinova.ai

BSH19‐PO‐078 : Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non‐Hodgkin Lymphoma

Researchers

Presenter

  • J. Gribben

Principal Investigators

  • K. Izutsu

  • N.H. Fowler

  • X. Hong

  • J. Zhu

  • H. Zhang

  • F. Offner

  • A. Scheliga

  • G. Nowakowski

  • A. Pinto

  • F. Re

  • L.M. Fogliatto

  • P. Scheinberg

  • I. Flinn

  • C. Moreira

  • D. Liu

  • S. Kalambakas

  • P. Fustier

  • C. Wu

  • J.P. Leonard

Medical Centers

  • Centre for Haemato-Oncology, Barts Cancer, London, United Kingdom

  • Charles University Hospital, , Pilsen, Czech Republic,

  • National Cancer Center Hospital, Tokyo, Japan

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Fudan University Shanghai Cancer Center, Shanghai, China

  • Beijing Sanhuan Cancer Hospital, Beijing, China

  • Tianjin Medical University Cancer Hospital, Tianjin, China

  • UZ Ghent, Ghent, Belgium

  • Instituto Nacional de Cancer - INCA, Rio De Janeiro, Brazil

  • Mayo Clinic, Rochester, United States

  • Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli

  • Azienda Ospedaliero-Universitaria, Udine, Italy

  • Hospital De Clinicas de Porto Alegre, Porto Alegre RS, Brazil

  • Division of Hematology, Hospital A Beneficência Portuguesa, Sao Paulo, Brazil

  • SCRI Tennessee Oncology Nashville, Nashville, United States

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

  • 1Celgene Corporation Summit NJ United States

  • Celgene Corporation, Boudry, Switzerland

  • Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital,New York,United States

Locations

  • United Kingdom

  • Czech Republic

  • Japan

  • United States

  • China

  • Belgium

  • Brazil

  • Italy

  • Portugal

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Mucosa-associated lymphoid tissue lymphoma

  • Non‐Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Neutropenia

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01938001

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved